All In Biotech

Free tool

FAERS Monitor: Lynparza

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208558 or its brand name (Lynparza, Olaparib). Reports on generic versions are filed under their own applications.

Reports

21,443

Serious

19,511

91% of reports

Hospitalization

3,959

Death reported

6,079

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death4,833
  • malignant neoplasm progression2,129
  • nausea1,903
  • fatigue1,836
  • anaemia1,670
  • off label use971
  • vomiting761
  • neuropathy peripheral709
  • drug ineffective689
  • asthenia650
  • diarrhoea638
  • decreased appetite565
  • disease progression537
  • myelodysplastic syndrome493
  • haemoglobin decreased456

Reports by year received

View as table
YearReports
20101
20126
20131
20146
2015372
2016506
2017649
2018851
20191,426
20202,047
20212,215
20222,367
20232,863
20243,375
20252,747
20262,011

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,032,716 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myelodysplastic syndromeSignal49334.631.615,506
malignant neoplasm progressionSignal2,12920.820.039,473
anaemiaSignal1,6708.78.311,304
neuropathy peripheralSignal7097.46.83,878
deathSignal4,8335.55.418,581
disease progressionSignal5374.54.11,443
haemoglobin decreasedSignal4564.44.01,183
decreased appetiteSignal5652.42.2459
nauseaSignal1,9032.42.31,547
fatigueSignal1,8362.32.21,421
asthenia6501.71.6188
vomiting7611.61.5169
off label use9711.11.07
diarrhoea6381.00.91
drug ineffective6890.50.5340

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.